Florian Buschek retweeted
If this post gets over 200k reactions, we’ll formally change our policy so that in reports, when someone “ran”, it will say “they skedaddled.”
$DRX.TO out with a massive win. It doubles revenues over the life of the contract and they are not even at capacity and still bidding on more work. 3 times 2027 ebitda is dirt cheap. Solid balance sheet and very attractive competitive environment.
Florian Buschek retweeted
It’s the 8 year anniversary of the podcast today. Below, the first 3 episodes of the pod, dropped on 11/18/18.
Just a little bit has happened in the world and markets over these last 8 years!
The VIX would make an all-time high of 83 and the 10-year an all-time low yield of 51 bps in 2020. The epic tightening cycle in 2022. The Tariff Tantrum in 2025. The oil shock and Iran war of 2026. This thing called AI is also worth a mention.
And US government debt outstanding has basically doubled from 21.8 to 40.7T.
277 episodes and a real privilege to host these discussions with some great thinkers on markets, the economy, and policy.
More to come! Thanks for listening.
Florian Buschek retweeted
Most interesting thing I read this week is about phone software for small businesses.
$CXDO pitched by @sammccolgan
Crexendo. Around 250 local telecom and IT providers rent its platform and sell phone service under their own brand, "much as an online shop runs on Shopify without its customers knowing". Over 8 million people make work calls on it, most never heard the name.
Stock has halved since June and closed Friday at $4.92. Every bear Sam talks to says the same thing, software growth is slowing. And licence sales did fall 25% in the first 9 months. Licences are the lumpy part though, capacity bought upfront in blocks, and new customers now start with smaller orders and top up as they move users across. The recurring line underneath grows 16 to 20% a year. Hold licences flat and software growth is back to about 13% in 2027 by Sam's maths.
For proof Sam went to BroadSoft, the incumbent in this exact market until Cisco bought it in 2018, which reported the same 2 lines for a decade. Its licence growth swung from -5% to +70%, back to roughly zero, up to 24%, down to -3%. Recurring line grew every quarter.
"The market is busy counting Crexendo's licence sales. I think it is missing the gorilla."
THE GORILLA
Management dropped pieces of it on calls and at conferences: what the AI receptionist earns per account, how many licensees resell it, a price range for call analysis, how fast the app store grows. "I have yet to see anyone put the pieces together." Sam did, and counts 5 income streams.
The number that matters. Crexendo makes about $80 a year from each business on a licensee's platform, and there are about 390,000 of them. CAIRO, the AI receptionist, earns it about $900 a year from each business that takes it.
THE NUMBERS
→ EBITDA (roughly cash profit before interest and tax) about $15M this year
→ Sam's base case: about $54M in 2028, about $40M if AI take-up is half the assumption
→ Analysts: $21M
→ Enterprise value about $150M at the $5.07 it was written at, so the price pays for almost none of it
THE DEALS
Spare cash goes into buying its own licensees at about 1.3x revenue. Same platform, so no migration risk. ESI cost about 10x EBITDA, about 8.4x after savings, and about 5.5x once Crexendo sells the AI add-ons to the customers it bought.
A year from now Sam values it at about $6.40 with no AI and no deals, $8.10 with the deals, $18 to $24 with the AI streams. First real test is year-end results, when management gives CAIRO numbers for the first time.
Sam and the fund are long.
"If I'm wrong, I own a growing, cash-generative business near its historical lows. If I'm even half right on AI, the shares are worth several times today's price."
Florian Buschek retweeted
Wentworth buys $51K of $DAIO.
DATA I/O CORP DAIO · William Wentworth, President · bought $51K · +37% stake · instruments for meas · filed 14:15 ET
My outlook on $ABVX - What is there to say that hasn't been said? Whatever, here I go anyway...
In the $83s right now I think it has to be one of the worst mispricings (and thus, hopefully, best opportunities) I have ever seen in biotech. Honestly, given the post P3 status of this asset...I would probably be pretty comfortable calling it "the" worst mispricing I've seen.
The stock's performance this year has *easily* been the most frustrating disappointment I've experienced in >10 years of doing this. The stock is down almost 40% YTD, and its underperformance versus the $XBI this year is nearly -70%.
What makes this price action so particularly infuriating is how incredibly positive their updates throughout the year have been.
I would've guessed that $ABVX languishing in the $80s would have been the result of a mixed UC maintenance readout, perhaps with a CR delta around 20% or below...The reality was *twice* that (~40%) - tying the best clinical remission data *ever* shown (by multi-black box warning drug Rinvoq). And on top of that we got an even bigger blue sky surprise with truly unheard of, unprecedented endoscopic remission rates...
...Then, on top of that, a few months later an unrelated trial reads out at UEGW that once and for all confirms that the endpoint GI docs should be treating to is...Endoscopic remission! The exact endpoint where the runner up to $ABVX isn't even visible in the rear view mirror...On their recent call, $ABVX management called this a "perfect storm". I agree. Not only did they present ER data so positive that nobody had even *modelled* for it as a *possibility*, but then just a few months later, that very endpoint becomes *THE* key endpoint for the disease...incredible!
I think it's really worth listening to yesterday's $DAIO earnings call...
Florian Buschek retweeted
Key date for market participates.
Everyone knows the market bottoms on GTA6 release date.
$USIO taking a beating on what I think were perfectly fine numbers. Still think this is a great opportunity here.
Florian Buschek retweeted
Anthropic published its IPO roadshow slides and presentation today.
Below, I provide some highlights.
Scroll through, and I've provided a link to all the slides at the end. 👇
1. $ANT is growing rapidly without burning cash and already has a fortress balance sheet.
Florian Buschek retweeted
What supposed to be the strongest earnings update, turned out to be disappointing throughout all RIN producers.
The overarching theme: none of them were able to actually capture strong spot-margins. For some it was stated as one-time operational issue ($DAR), others have to prove the market they are capable of achieving it.
As for $FF, I will keep it brief here since I covered it in detail in the subscriber discord.
First: management has done a poor job of communicating what has happened/ what drives economics here. I also think FF is a weird company, that no one really understands. No real analyst coverage and the chemical guys don’t get biodiesel and the RIN guys prefer $DAR or $CLMT.
The key to understand is that they have one big plant from where they operate both segments. Overhead is shared and allocation to COGS depends on utilization. Hence, if one segment operates at lower utilization, like the chemical segment did this quarter, it drags down the other segments GM.
This is one explanation, why margin looked extremely weak on surface. It doesn’t explain the entire gap to spot-margin but add to that some timing lag, and you can get a sense that actual realized margin on each gallon was not as bad as the market thinks after this sell-off.
Ultimately, we will know from Q4 onwards how close they can get to spot-margins.
Florian Buschek retweeted
New post with some weekend Thoughts: Datacenters, AI Stocks and the AI Religion
basehitinvesting.substack.co…
Florian Buschek retweeted
A friendly reminder that @KeithMcCullough's "Family Office" has returned by ~4% a year annualized.
(Analysis based upon stitching together ~10 self-published screen shots of his account over time: teapawt.org/choffstein/status/1843…)
Replying to @KeithMcCullough
Maybe, but I'd be less inclined to put it here.
"Among tactical allocation and multi-asset dynamic funds (around 400+ funds in Morningstar/Lipper categories), HECA ranks near the very bottom (410 out of ~415 peers)."
Florian Buschek retweeted
Much respect to this guy. Not only has he covered the name, along the RIN thesis, better than any other for years, all publicly, but also has no ego to point out what went worse than expected.
$CLMT no doubt had a great quarter. EBITDA came in 10% above the highest street estimate. But it did come in ~$50-100M less than my expectation primarily on MRL RD index capture (-$40M) & spot base oil cracks vs. contracts. I have to revise my peak cycle numbers down. I also think the mkt is now pricing in peak earnings rolling over imminently which means lower stock from multiple compression, which could prove to be very wrong in the near term.












































